Author:
Anshu Aseem Kumar,Nath Akhileshwari,Prinyanka ,Sinha Neha,Sinha Priyanka,Sinha Shreya,Singh J. K.
Publisher
Springer Science and Business Media LLC
Subject
Pathology and Forensic Medicine,Anatomy
Reference38 articles.
1. Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155–168
2. Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S et al (1998) neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 16:1340–1349
3. Baselga J, Seidman AD, Rosen PP et al (1997) Her-2 overexpression and paclitaxel sensitivity in breast cancer. Therapeutic implication. Oncology (Huntingt) 11(suppl 2):43–48
4. Berry DA, Muss HB, Thor AD, Dressler L, Liu ET, Broadwater G et al (2000) HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 18:3471–3479
5. Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Ryden S et al (1994) ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 81:137–144